window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 1, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

retinal disease

  • Biotech,Cell & Gene Therapy,Clinical Development,Clinical Trials,European biotech,Opthalmology

    PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy

    PulseSight Therapeutics has completed dosing in its Phase 1 clinical [...]

    January 26, 2026
  • Biotech,Cell & Gene Therapy,Clinical studies,Clinical Trials,Drug Development,Opthalmology

    Complement Therapeutics receives FDA IND clearance for CTx001 to enter Opti-GAIN trial in geographic atrophy

    Complement Therapeutics GmbH (CTx) has received clearance from the FDA [...]

    October 8, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ARTCLINE completes enrolment in septic shock trial for ARTICE therapy
    Categories: Biotech, Cell & Gene Therapy, Clinical Development, Clinical Trials, Infectious Diseases, Pharmaceuticals and therapeutics
  • SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week
    Categories: CDMOs & Manufacturing, Healthcare leadership, Market Access & Commercialization, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top